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OBJECTIVES: The department of Dermatology of the
University hospital Maastricht performed a randomised
trial to compare the cost-effectiveness of surgical excision
(SE) and Mohs Micrographic surgery (MMS) in a group
of patients with primary and recurrent facial Basal Cell
Carcinoma (BCC). METHODS: Hospital costs, recur-
rence rates and quality of life data (NHP and STAI) were
collected during a time period of 18 months. The Incre-
mental Cost Effectiveness Ratio’s were calculated based
on incremental costs per recurrence avoided, both for
primary and recurrent BCC. The reliability of the ICER
was estimated by means of bootstrap simulations.
RESULTS: In total 408 primary BCC and 204 recurrent
BCC were randomised to either SE or MMS. The ICER
for primary BCC amounted to €25.200. Seventy-four
percent of all ratio’s were within the quadrant where
MMS is more effective but also more costly. Twenty-four
percent of all ratio’s were in the quadrant where SE dom-
inates. The ICER for recurrent BCC amounted to €7.733.
All ratios were within the quadrant where MMS is more
effective but also more costly. For both primary and
recurrent BCC group, quality of life was not statistically
signiﬁcant different between SE and MMS. CONCLU-
SIONS: Based on costs and the recurrence rates, it is not
cost-effective to introduce MMS for primary BCC on a
large scale. However, other aspects like the patient per-
spective have not been examined in this study. It is pos-
sible that patients have a speciﬁc preference for either one
of the two treatment modalities. For the recurrent BCC
both ICER and bootstrap results should be treated with
caution since only ﬁfty percent of the patients with recur-
rent BCC have completed their 18-month follow-up. 
Possible changes in the recurrence rate may have a con-
siderable effect on the ﬁnal cost-effectiveness ratio of this
group.
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OBJECTIVES: To evaluate cost implications of oral
chemotherapy with capecitabine vs. standard ﬂuoropy-
rimidine-therapies (Mayo Clinic and AIO/Ardalan-
regimen), in different treatment settings in Germany.
METHODS: Costs of ﬂuoropyrimidine-therapies were
evaluated for the ofﬁce-based setting. Physician’s fees (89
quarterly fee-listings, 26 patients, 6 ofﬁce-based oncolo-
gists), drug and pharmacy costs and costs for venous 
port systems and single-use pumps were included.
Capecitabine treatment costs were assumed to be identi-
cal to the cost of the Mayo Clinic-regimen, except drug
administration and acquisition. Based on the frequency
of administration of active drugs by ofﬁce-based oncolo-
gists costs were modelled for 4 scenarios in the hospital
sector, i.e. in- and outpatient treatment in university- and
municipal hospitals. A third-party payer perspective was
adopted. Market research data on frequency and setting
of use of the evaluated regimens were used to estimate
potential overall cost implications. RESULTS: Treatment
costs for a 6-months course in the ofﬁce-based setting was
most expensive with the AIO/Ardalan regimen (€20,358)
and cheapest with capecitabine (€4776). In contrast, 
the AIO/Ardalan-protocol was cheaper than the Mayo
Clinic-protocol in all hospital settings (AIO/Ardalan
€2588–13,434; Mayo Clinic 4072–21,138). Potential
direct yearly savings by switching patients from Mayo-
Clinic- or AIO/Ardalan-regimen to oral capecitabine were
estimated at €78–84 Mio. CONCLUSION: The most
expensive treatment options were the AIO/Ardalan-pro-
tocol in the ofﬁce-based setting and the Mayo Clinic pro-
tocol in the hospital setting. Interestingly, remuneration
for hospitals is unlikely to be cost covering for some treat-
ment situations, in particular with the AIO/Ardalan-
regimen. Capecitabine emerged as the cheapest option 
in the ofﬁce-based setting (NA for hospital due to 
oral administration). Transferring patients to oral
capecitabine is likely to result in substantial cost savings,
estimated at €78–84 Mio annually. Savings are likely to
be substantially higher if combination therapies with
irinotecan or oxaliplatin are considered.
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OBJECTIVE: Gastric cancer is the most frequent cancer
in Japan and is an important cause of growing national
Health care costs. However, few studies focusing on the
costs of treating gastric cancer in Japan have been con-
ducted. We previously reported the costs of chemother-
apy for advanced or recurrent gastric cancer. Our results
have shown that the costs of hospitalization and sup-
